Fig. 1

Establishing steatosis model with human fetal liver organoid and screening the drugs/targets with steatosis reducing effect. A Schematic of steatosis modeling with human fetal liver organoid by introducing variant triggers. B Schematic of drug screening coupled RNA-seq analysis and CRISPR-LOF screening with subsequent functional validation